Corporate Overview

SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world. The company has active programs in oncology, autoimmune and infectious diseases, as well as additional exploratory initiatives to support future pipeline growth. SQZ’s proprietary Cell Squeeze® technology can deliver multiple biological materials into many cell types, offering the ability to engineer a broad range of potential therapeutics.

With clinical production timelines already under 24 hours, the company has the potential to enable broader patient accessibility through point-of-care manufacturing implementation across multiple therapeutic programs. The company's approach could also improve a patient’s treatment journey with no planned hospitalization or preconditioning treatment. The company’s first therapeutic efforts seek to generate target-specific immune responses, both through activation for the treatment of solid tumors and infectious diseases, and by immune tolerance for the treatment of autoimmune diseases.

Learn more: SQZ Investor Factsheet

By the Numbers

1000

Times more efficient CD8 T cell activation with our SQZ APC platform over traditional vaccine approaches

24

Hours or less to manufacture all patient doses for our current cell therapies

10B

Cells engineered in under a minute

1

Core Cell Squeeze® technology, Unlimited possibilities

Latest News

View all news

Latest Events

View All Events